Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lesser-known lobular breast cancer on the rise in U.S. women

2.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

3.

It Is Not Just the Royals Who Go Through Cancer.

4.

Pressing the Sleep button could have a positive impact on cognition.

5.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot